AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 4 out of 5

Results 1 - 20 of 36 : 1 2 Next »

Recs

0
Member Avatar moonlightsail (39.37) Submitted: 3/19/2015 4:35:51 PM : Outperform Start Price: $61.50 ABBV Score: -4.60

Drug company with a dividend.

Recs

0
Member Avatar ZenRiDr (40.20) Submitted: 3/2/2015 8:21:06 PM : Outperform Start Price: $60.35 ABBV Score: -1.97

Will have about 15% share if HCV market. Humira.

Recs

0
Member Avatar Dreadnought (61.47) Submitted: 2/28/2015 12:01:12 AM : Outperform Start Price: $60.30 ABBV Score: -2.21

I am going to guess that this company supports Richard Branson and Jeb Bush at the poles. Then again, I might just be thinking about GILD.

Recs

0
Member Avatar bdbcalm (< 20) Submitted: 2/15/2015 4:54:27 PM : Outperform Start Price: $57.04 ABBV Score: +3.18

Sold off due to patent cliff concerns and Hep C drug discounts. I believe this is an overreaction and the stock will recover. There is more in the pipeline than the P/E - 13 - would imply.

Recs

0
Member Avatar Reddog4Sina (64.33) Submitted: 2/5/2015 2:35:07 PM : Outperform Start Price: $57.95 ABBV Score: -0.71

Humira. R+D. Growth. Underappreciated performance.

Recs

3
Member Avatar TMFSpiffyPop (99.55) Submitted: 1/9/2015 1:01:03 PM : Underperform Start Price: $65.21 ABBV Score: +12.64

This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For these reasons (and a couple others, besides), I'm going to thumb this down for the next three years -- a fine company that we can all cheer for, but I'm betting the stock underperforms. I'm emboldened by my Stock Advisor teammate TMFWillSomers who wrote the following for me in an internal research report:

"Although AbbVie has a successful track record and plenty of money to spend or R&D or acquisitions, it faces a huge challenge in filling the sales hole that will open up when Humira comes off patent. Humira is currently the 2nd best-selling drug of all time, and it may even surpass Lipitor as the #1 best-selling drug ever. No easy shoes to fill – especially as biosimilars seem to be making progress. The hep-C treatment will be a multi-billion dollar blockbuster, but it may not be enough."

Brendan gave it a 40% chance to beat the market so I'm siding with my guy. And if he's right, this is partly how you achieve a high CAPS rating -- thumb differently from 99% of others.... Underperform.

Recs

0
Member Avatar gatzbp (94.91) Submitted: 11/14/2014 5:12:45 PM : Underperform Start Price: $63.61 ABBV Score: +10.58

Hep C market is a competitive space with uncertainty on both the asking price (of producers) and the paying price (consumers, medical plans).

Recs

0
Member Avatar manirg (85.87) Submitted: 10/29/2014 3:26:41 PM : Outperform Start Price: $56.94 ABBV Score: +0.13

undervalued

Recs

0
Member Avatar TMFHelical (99.20) Submitted: 10/20/2014 11:24:48 AM : Outperform Start Price: $54.29 ABBV Score: +3.63

Shire aside, AbbVie stands to gain market share in Hep C due to the market's anger at the pricing from Gilead. Approval likely pending.

And if not, there is still Humira, which will be only modestly affected by biosimilars over time.

Recs

0
Member Avatar d3ming (< 20) Submitted: 9/3/2014 5:30:26 PM : Outperform Start Price: $54.54 ABBV Score: +3.09

anti-aging

Recs

0
Member Avatar sjm9 (64.63) Submitted: 8/26/2014 2:05:19 PM : Outperform Start Price: $54.94 ABBV Score: +2.17

Their pipeline includes some some opportunities, including a potential blockbuster hep-C drug.

Recs

0
Member Avatar FloydParks (54.51) Submitted: 8/16/2014 5:56:58 PM : Outperform Start Price: $53.59 ABBV Score: +2.87

Dividends will become increasingly valued in the next few years

Recs

0
Member Avatar cryptelligence (72.82) Submitted: 7/3/2014 6:48:36 PM : Outperform Start Price: $56.62 ABBV Score: -2.41

Algae Play

Recs

1
Member Avatar BaseBawl (< 20) Submitted: 5/29/2014 9:44:04 AM : Outperform Start Price: $53.09 ABBV Score: +1.10

4 more dogs of the dividend aristocrats that I didn't already have. Hudspeth.

Recs

0
Member Avatar ZipMeck (67.98) Submitted: 3/2/2014 11:51:23 AM : Outperform Start Price: $48.78 ABBV Score: +6.63

Have a few in the pipeline coming up in phase 111 and also reviews coming up.

Recs

0
Member Avatar TerryFool (78.22) Submitted: 2/6/2014 9:36:31 AM : Outperform Start Price: $49.12 ABBV Score: +5.88

invest, ABBV BP 47.0 TP 54.3 2.2 5star

Recs

0
Member Avatar rjs157 (63.85) Submitted: 1/21/2014 4:39:22 PM : Outperform Start Price: $48.43 ABBV Score: +7.37

ABT spin off, will do well

Recs

0
Member Avatar drugstock2 (< 20) Submitted: 1/19/2014 3:43:50 PM : Outperform Start Price: $48.50 ABBV Score: +7.34

Humira will provide ABBV with a steady stream of cash to support a healthy dividend, and fund new product development and acquisitions.

Recs

0
Member Avatar grankh (85.88) Submitted: 12/13/2013 1:04:45 PM : Outperform Start Price: $49.47 ABBV Score: +2.98

I own this stock through my Investment Club, which bought it this month.

Since it was only spun off from Abbott Labs earlier this year, I don't have as much data on this stock as I would normally like before purchasing it. But the club liked it, so we bought it.

Sales have increased at an annual compound rate of over 5% since 2011. EPS increased at a compound rate of over 12% from 2010 to 2012. The profit margin has been fluctuating a lot, but was 31% last year, which is pretty good. The return-on-equity was 47%, which is pretty good. However, the debt-to-equity was 423%, which is pretty high in my book, so Abbott Labs loaded up their spin off with debt before spinning it off. Not amongst my favorite things. The current P/E is more than double its highest P/E from last year, so the stock seems expensive on that metric. The PEG ratio comes in at 2.35, which is very expensive. The company pays about a 3% dividend, which is pretty good.

I show this stock as a Hold, with an expected annual return of about 8%. The person who presented the stock thinks we will get significantly more than that. We'll have to wait and see which of us is correct.

Recs

0
Member Avatar line70day (< 20) Submitted: 11/6/2013 3:48:20 PM : Outperform Start Price: $50.64 ABBV Score: -0.16

Jan 1 20113 ABBV became independent
Cash flow & equivalent at end of period
$8,743 2013 $74 2012
rev growth 1 yr 5.40% eps 53.70%
rev trailing 12Q 9.02 B
ers 1.27ytd
div ytd 0.80

Results 1 - 20 of 36 : 1 2 Next »

Featured Broker Partners


Advertisement